KZR - BULLISHPurchased this stock at .85 cents on the 15th, based on an article on oct 10th, today news came out states:
Regulatory Approval: The approval from China's National Medical Products Administration (NMPA) for the Phase 2b PALIZADE trial signifies regulatory confidence in the potential of zetomipzomib. Regulatory approvals are critical milestones in drug development, enhancing the credibility and prospects of the drug's success.
Innovative Treatment: Zetomipzomib is described as a novel, first-in-class selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. The introduction of innovative treatments into the market, especially those targeting conditions with unmet medical needs like lupus nephritis, can lead to significant commercial success.
Strategic Collaboration and Market Rights: Everest Medicines' partnership with Kezar Life Sciences and the exclusive rights to develop and commercialize zetomipzomib in key Asian markets (Greater China, South Korea, and Southeast Asia) open substantial market opportunities. Access to these markets, particularly China with its large patient population for lupus nephritis, presents a significant growth avenue for Everest and by extension, for Kezar through collaboration.
Potential Market Impact: The emphasis on addressing lupus nephritis, a common and severe autoimmune disease leading to kidney failure, targets a considerable market need. Successful trial outcomes could position zetomipzomib as a leading treatment option, driving demand and generating substantial revenue.
Overall, the combination of regulatory approval, the introduction of a potentially groundbreaking treatment, strategic collaborations, and access to large markets underlines a bullish outlook for Everest Medicines and Kezar Life Sciences, reflecting investor optimism about their future growth and profitability.
Sold for a quick 13% profit, if we move back lower ill re buy, if not eh. If i get back in and we head into the 85 cents, target 1.37 which is 618 on the micro, or 2.25 which is 618 on the macro.
good luck traders.
KZR trade ideas
$KZR Long term PT 35 and higherKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
KZR Fib Retracement: Next Target $5 + Big PotentialPlease keep in mind not to take anything I say seriously, as this is of opinion basis and not face value. That being said, let us get to the analysis. I believe through the Fibonacci retracement, we can look at a short target of $5 for the next trend analysis goal of Kezar life sciences. Kezar had a huge decline in price over the past year, but the strong support may out do the negative bids and resistance. They are also expected to go to the next stage of their drug development and testing pipeline before the end of the year (according to their site). It is too early to call a long on this, but given the potential and current support, I am at least calling a short for this with a profit target of $5 being hit soon. It could even pass a $15 threshold in price before the end of the year, but a long call is still too early.
KZR - Bullish Divergence Found. Possible Change In MomentumKezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
SHORT INTEREST
1.12M 08/15/19
P/E Current
-1.50
P/E Ratio (with extraordinary items)
-2.32
Average Recommendation: BUY
Average Target Price: 24.33